Korro Bio initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Korro Bio with an Outperform rating and $70 price target. Korro Bio’s approach in RNA editing has clear strategic interest that may have an easier path to approval and commercial uptake vs. DNA editing, the analyst tells investors in a research note. While the story will take time to play out, RBC likes impressive preclinical data and a team that is poised to execute.